Class information for:
Level 1: EMESIS//CHEMOTHERAPY INDUCED NAUSEA AND VOMITING//DELAYED EMESIS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
745 3031 29.5 68%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
2076 4805 EMESIS//ANTIEMETICS//PALONOSETRON

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 EMESIS Author keyword 340 58% 13% 396
2 CHEMOTHERAPY INDUCED NAUSEA AND VOMITING Author keyword 248 88% 4% 117
3 DELAYED EMESIS Author keyword 212 95% 2% 72
4 PALONOSETRON Author keyword 197 82% 4% 113
5 ANTIEMETIC Author keyword 177 66% 5% 162
6 GRANISETRON Author keyword 169 58% 6% 195
7 NAUSEA Author keyword 140 31% 13% 379
8 APREPITANT Author keyword 131 63% 4% 133
9 ANTIEMETICS Author keyword 114 45% 6% 189
10 VOMITING Author keyword 107 26% 12% 349

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 EMESIS 340 58% 13% 396 Search EMESIS Search EMESIS
2 CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 248 88% 4% 117 Search CHEMOTHERAPY+INDUCED+NAUSEA+AND+VOMITING Search CHEMOTHERAPY+INDUCED+NAUSEA+AND+VOMITING
3 DELAYED EMESIS 212 95% 2% 72 Search DELAYED+EMESIS Search DELAYED+EMESIS
4 PALONOSETRON 197 82% 4% 113 Search PALONOSETRON Search PALONOSETRON
5 ANTIEMETIC 177 66% 5% 162 Search ANTIEMETIC Search ANTIEMETIC
6 GRANISETRON 169 58% 6% 195 Search GRANISETRON Search GRANISETRON
7 NAUSEA 140 31% 13% 379 Search NAUSEA Search NAUSEA
8 APREPITANT 131 63% 4% 133 Search APREPITANT Search APREPITANT
9 ANTIEMETICS 114 45% 6% 189 Search ANTIEMETICS Search ANTIEMETICS
10 VOMITING 107 26% 12% 349 Search VOMITING Search VOMITING

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CISPLATIN INDUCED EMESIS 696 76% 16% 489
2 MODERATELY EMETOGENIC CHEMOTHERAPY 597 86% 10% 301
3 INDUCED NAUSEA 540 80% 11% 333
4 HIGH DOSE METOCLOPRAMIDE 461 81% 9% 276
5 DELAYED EMESIS 321 88% 5% 150
6 INDUCED EMESIS 294 60% 10% 318
7 CHEMOTHERAPY INDUCED NAUSEA 161 50% 8% 231
8 ONDANSETRON 152 29% 15% 442
9 ONDANSETRON PLUS DEXAMETHASONE 138 83% 3% 78
10 ANTAGONIST APREPITANT 122 79% 3% 77

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines 1999 318 208 96%
Drug therapy: Chemotherapy-induced nausea and vomiting 2008 183 84 90%
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006 2006 298 87 100%
Management of Chemotherapy-Induced Nausea and Vomiting Focus on Newer Agents and New Uses for Older Agents 2013 19 57 81%
5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting - A comparison of their pharmacology and clinical efficacy 1998 148 49 92%
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference 2006 150 30 100%
International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice 2014 8 50 94%
Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review 2014 9 17 82%
Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting 2012 31 35 77%
Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis 2014 12 83 54%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 EMESIS GRP 22 81% 0.4% 13
2 BIOBEHAV MED ONCOL PROGRAM 5 41% 0.3% 9
3 STRATEG PROD DEV 4 67% 0.1% 4
4 ONCOL 54 B1 4 75% 0.1% 3
5 EMESIS GRPBRAIN GUT 3 100% 0.1% 3
6 UNIT CELL THER Y TRANSPLANTAT 3 100% 0.1% 3
7 OSTEOPATH MED PACIFIC 3 15% 0.7% 20
8 INTERNAL MED ONCOL SCI 2 29% 0.2% 7
9 HOKKAIDO NURSING 2 67% 0.1% 2
10 SECT MED SUPPORT CARE 2 67% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000146143 H 1 AND H 2 RECEPTORS//STRUCTURED PROTEINS//CATECHOLAMINE NEURON
2 0.0000128738 SECT MOL ECOGENET//BROMOPRIDE//METOCLOPRAMIDE HYDROCHLORIDE
3 0.0000119822 POSTOPERATIVE NAUSEA AND VOMITING//VOMITING ANTIEMETICS//VOMITING NAUSEA
4 0.0000101691 5 HT3 RECEPTOR//5 HT3 RECEPTORS//5 HT3A
5 0.0000062418 MALIGNANT BOWEL OBSTRUCTION//BOWEL OBSTRUCTION//VENTING GASTROSTOMY
6 0.0000061296 MOTION SICKNESS//MOT SICKNESS HUMAN PERFORMANCE//SIMULATOR SICKNESS
7 0.0000043471 CONDITIONED TASTE AVERSION//REWARD COMPARISON//INSULAR CORTEX
8 0.0000041847 5 HT4 RECEPTORS//5 HT4 RECEPTOR//GR 113808
9 0.0000039019 CISAPRIDE//KW 5092//CINITAPRIDE
10 0.0000037299 SUCTION CAPSULE//NORRKOPING HOSP//SUCTION BIOPSY